Tafamidis
- Generic Name
- Tafamidis
- Brand Names
- Vyndamax, Vyndaqel
- Drug Type
- Small Molecule
- Chemical Formula
- C14H7Cl2NO3
- CAS Number
- 594839-88-0
- Unique Ingredient Identifier
- 8FG9H9D31J
- Background
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal.
Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
- Indication
Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
- Associated Conditions
- Cardiomyopathy
- Associated Therapies
- -
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1733
- Registration Number
- NCT02791230
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
🇺🇸University of Maryland, Baltimore, Baltimore, Maryland, United States
A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02746926
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Comparing Amounts of Tafamidis In The Blood Without Food
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02697864
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02534740
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02406560
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Bioequivalence Study Comparing Two Different Tafamidis Formulations
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT02217813
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02189330
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 441
- Registration Number
- NCT01994889
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸UAB Hospital Department of Pharmacy IDS, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona - Mayo Clinic Speciality Building, Phoenix, Arizona, United States
Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01655511
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT01435655
- Locations
- 🇯🇵
Kumamoto University Hospital/Department of Neurology, Kumamoto-shi, Kumamoto, Japan
🇯🇵Shinshu University Hospital/Department of Medicine (Neurology and Reumatology), Matsumoto-shi, Nagano, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.